|
Novo Nordisk Seeks FDA Approval for Higher 7.2 mg Dose of Wegovy
|
Written by: J. Smith |
Hits: 518
|
|
Novo Nordisk Reports Strong Phase 2 Results for Amycretin in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 434
|
|
Oral Semaglutide Does Not Slow Alzheimer’s Progression: How Today’s Results Fit the Larger Story
|
Written by: J. Smith |
Hits: 448
|
|
Zealand Pharma Pauses Development of Dapiglutide
|
Written by: J. Smith |
Hits: 515
|
|
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
|
Written by: J. Smith |
Hits: 332
|
|
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
|
Written by: J. Smith |
Hits: 299
|
|
Terns Ends Development of Oral Obesity Drug After Phase 2 Results
|
Written by: J. Smith |
Hits: 574
|
|
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 384
|
|
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
|
Written by: J. Smith |
Hits: 259
|
|
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
|
Written by: J. Smith |
Hits: 706
|
